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1. Introduction 
Malignant melanoma is a deadly disease in which standard treatment options have remained 
remarkably static over the past 30 years (Sullivan & Atkins, 2009). At present, the incidence of 
melanoma continues to increase despite public health initiatives that have promoted 
protection against the sun. Thus, during the past ten years, the incidence and annual mortality 
of melanoma has increased more rapidly than any other cancer and according to an American 
Cancer Society estimate, there will have been approximately 68,720 new cases of invasive 
melanoma diagnosed in 2009 in the United States, which resulted in approximately 8,650 
deaths (American Cancer Society, 2009). Unfortunately, the increase in incidence has not been 
paralleled by the development of new therapeutic agents with a significant impact on survival. 
Although many patients with melanoma localized to the skin are cured by surgical excision, 
increased time to diagnosis is associated with higher stage of disease, and those with regional 
lymphatic or metastatic disease respond poorly to conventional radiation and chemotherapy 
with 5-year survival rates ranging from 10 to 50% (Tawbi & Buch, 2010). Currently, limited 
therapeutic options exist for patients with metastatic melanomas, and all standard 
combinations currently used in metastasis therapy have low efficacy and poor response rates. 
One example of the complications involved in melanoma chemotherapy is the limited 
effectiveness of antifolates. Although methotrexate (MTX), the most frequently used antifolate, 
is an efficient drug for several types of cancer, it is not active against melanoma (Kufe et al., 
1980). Undoubtedly, unravelling the mechanism of the resistance of melanomas to this drug 
could help to improve current therapeutic approaches. Moreover, it could help to develop a 
novel generation of antifolate drugs that overcome resistance problems and present low 
toxicity for the prophylaxis and treatment of melanoma. 
2. Mechanisms of resistance of melanoma to classical antifolates 
Dihydrofolate reductase (DHFR; 5,6,7,8-tetrahydrofolate: NADP+ oxidoreductase, EC 1.5.1.3) 
catalyzes the reduction of 7,8-dihydrofolate (DHF) to 5,6,7,8-tetrahydrofolate (THF) in the 
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presence of coenzyme NADPH as follows: DHF + NADPH + H+  THF + NADP+. This 
enzyme is necessary for maintaining intracellular pools of THF and its derivatives which are 
essential cofactors in one-carbon metabolism. Coupled with thymidylate synthase (Lockshin et 
al., 1979), it is directly involved in thymidylate (dTMP) production through a de novo pathway. 
DHFR is therefore pivotal in providing purines and pyrimidine precursors for the biosynthesis 
of DNA, RNA and amino acids. In addition, it is the target enzyme (Blakley, 1969) for 
antifolate drugs such as the antineoplastic drug MTX and the antibacterial drug trimethoprim 
(TMP). The mechanisms of resistance to MTX have been extensively studied, mainly in 
experimental tumors propagated in vitro and in vivo (Kufe et al., 1980; Zhao & Goldman, 2003; 
Assaraf, 2007); however, the specific basis for the resistance of melanoma cells to MTX is 
unclear. During decades the mechanism of resistance of melanoma to MTX was associated 
with general mechanisms of resistance detected in other epithelial cancer cell including 
reduced cellular uptake of this drug, high intracellular levels of DHFR and/or insufficient rate 
of MTX polyglutamylation, which diminishes long-chain MTX polyglutamates from being 
preferentially retained intracellularly (Assaraf, 2007). However, recently, a melanoma-specific 
mechanism of resistance to cytotoxic drugs, including MTX, has been described (Chen et al., 
2006; Sánchez-del-Campo et al., 2009a; Xie et al., 2009). Experiments from our laboratory and 
others provide evidences that melanosomes contribute to the refractory properties of 
melanoma cells by sequestering cytotoxic drugs and increasing melanosome-mediated drug 
export. Concretely, we have described that folate receptor  (FR)-endocytotic transport of 
MTX facilitates drug melanosomal sequestration and cellular exportation in melanoma cells, 
which ensures reduced accumulation of MTX in intracellular compartments (Sánchez-del-
Campo et al., 2009a). 
An important observation in this study was that MTX was a cytostatic agent on melanoma 
cells. These cells were resistant to MTX-induced apoptosis but responded to the drug by 
arresting their growth. A similar response was observed when the murine B16/F10 
melanoma cell line was grown in low folate. After 3 days in folate-deficient medium the 
cells had restricted proliferative activity and also increased their metastatic potential 
(Branda et al., 1988). Taking this into consideration, the results indicate that MTX might also 
induce depletion of intracellular reduced folate coenzymes by reducing their transport 
though the FR and/or competing with them for the reduced folate carrier (RFC). 
Melanoma cells may be highly sensitive to intracellular depletion of folate coenzymes, and 
in this situation may enter into a “latent” state. This form of melanoma should indeed be 
highly resistant to MTX, since antifolate drugs are more effective on fast-dividing cells, 
which require continuous DNA synthesis. Most likely, the high increases of DHFR 
expression in cells treated with MTX (Kufe et al., 1980) would represent an adaptation 
mechanism that allows cells to survive with low intracellular concentrations of folate 
coenzymes. Increasing the recycling of folate molecules the cells would maintain other 
cellular functions that are dependent on folate coenzymes, such as the synthesis of purines, 
pyrimidines, amino acids and methylation reactions. The presence of this “latent” form of 
melanoma should be critical for the resistance to MTX during in vivo therapies. Although 
MTX chemotherapy could initially halt the development of the tumor, after clearance of the 
drug from the body the melanoma cells may reinitiate their progression, possibly with an 
increased metastatic potential (Branda et al., 1988). 
A defect in intracellular folate retention is another recognized mechanism of drug resistance 
(Assaraf, 2007; Gaukroger et al., 1983; Kufe et al., 1980; Zhao and Goldman, 2003). In 
addition to a decrease in antifolate polyglutamylation, melanoma cells may also export 
www.intechopen.com
 Novel Antifolates as Produgs for the Treatment of Melanoma 
 
103 
cytotoxic drugs by melanosome sequestration (Chen et al., 2006). The results presented in 
this study indicated that drug exportation was an operative mechanism of resistance to MTX 
in melanoma cells. Although the mechanism by which cytotoxic drugs are sequestered into 
melanosomes remains unclear, we demonstrated that MTX-melanosome trapping may be a 
consequence of its FR-endosomal transport (Sánchez-del-Campo et al., 2009a). To test the 
importance of this process on the resistance of melanoma to antifolates, we silenced the 
expression of the melanosomal structural protein gp100/Pmel17, which is known to play a 
critical role in melanosome biogenesis (Theos et al., 2005). Recently, Xie and collaborators 
(2009) provided the first direct evidence that disruption of the process of normal 
melanosome biogenesis, by mutation of gp100/Pmel17, increased sensitivity to cisplatin. We 
also observed that effective silencing of gp100/Pmel17 significantly increased the sensitivity 
of melanoma cells to MTX, favouring MTX-induced apoptosis. This observation strongly 
supports the hypothesis which indicates that melanosome biogenesis is a specialization of 
the endocytic pathway (Raposo and Marks, 2002; 2007); however, the exact mechanism by 
which MTX induces abnormal trafficking of early endosomes in melanoma cells, favoring 
the exportation of melanosomes, is still unclear. Whether MTX blocks the formation of 
carrier vesicles operating between early and late endosomes, inhibits the delivery of 
endocytosed material from endosomes to lysosomes, promoting, thus, the generation of 
exosomes (Raposo and Marks, 2007) and/or induces a failure of lysosomal acidification, 
which is essential for normal endocytosis (Liang et al., 2003), remains to be determined.  
To explore the relationship between MTX exportation and melanosome trafficking, we 
studied the possible interaction of MTX with melanin (Sánchez-del-Campo et al., 2009a). 
Such interaction was confirmed by incubating this drug with synthetic 3,4-
dihydroxyphenylalanine (DOPA)-melanin. Importantly, folic acid and 5-methyl-THF, the 
natural source of cellular folates, did not appear to interact with synthetic DOPA-melanin. A 
comparison of the interaction of several folates (folic acid and 5-methyl-THF) and antifolates 
(MTX and aminopterin) with synthetic DOPA-melanin indicated that the double amino 
group of the pterin ring is an important molecular requirement for the drug-melanin 
interaction. Therefore, the physiological importance of the high affinity of melanin for 
antifolates, such as MTX and aminopterin, for drug melanosomal sequestration is also 
another important issue that remains to be addressed. Endocytic transport of molecules 
involves several processes, including the fusion of early and late endosomes and the 
dissociation of receptor-ligand complexes through the acidic pH of preformed vesicles 
(Sabharanjak and Mayor, 2004). After melanosome biogenesis from MTX-loaded 
endosomes, dissociated MTX could be trapped in the melanosomes by its interaction with 
melanins. In contrast, folate substrates would not be sequestered in melanosomes due to 
their low affinities for melanin; facilitated by the acidic pH of this organelle, uncharged 
reduced folates would leave the melanosome by passive diffusion and reach the cytosol, 
where they would become available for cellular functions. Therefore, elucidation of the 
molecular basis for the (anti)folate interaction with melanins could have important 
therapeutic implications, and this study might be used as a guide for the synthesis of new 
antifolates or for using existing antifolates in ways that escape melanin trapping.  
In addition to these cellular mechanisms of resistance to MTX in melanoma, other 
mechanism that includes liver transformation of the drug has also been reported. A 
paradoxical response of malignant melanoma to MTX in vivo and in vitro has been described 
(Gaukroger et al., 1983). The authors observed that MTX showed consistent cytotoxicity for 
melanoma cells in vitro but was ineffective at equivalent concentrations in vivo. MTX 
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undergoes oxidation to its primary metabolite 7-hydroxy-MTX (7-OH-MTX) in the liver by 
the enzyme aldehyde oxidase (Assaraf, 2007) and therefore, this transformation has been 
proposed as a novel mechanism of resistance to explain this paradox (Gaukroger et al., 1983; 
Assaraf, 2007). In contrast to the large body of literature available on the multiple modalities 
of MTX resistance, very little is known regarding the ability of 7-OH-MTX to provoke 
antifolate-resistance phenomena that may disrupt MTX activity. Recent studies seem to 
indicate that 7-OH-MTX which exceeds by far MTX in the plasma of MTX-treated patients 
can provoke distinct modalities of antifolate-resistance that severely compromise the 
efficacy of the parent drug MTX (Joerger et al., 2006).  
3. The antifolate activity of tea catechins 
Recent studies have presented data that show a variety of biological activities of tea 
catechins, compounds which constitute about 15% (dry weight) of green tea (Mukhtar & 
Ahmad, 2000; Fujiki et al., 2002). Green tea catechins include: (-)-epigallocatechin gallate 
(EGCG), (-)-epigallocatechin (EGC), (-)-epicatechin gallate (ECG) and (-)-epicatechin (EC). 
EGCG is the most abundant (one 240 mL cup of brewed tea contains up to 200 mg EGCG), 
and many health benefits, including antioxidant, antibiotic and antiviral activities, have 
been attributed to this compound (Yam et al., 1998; Mabe et al., 1999; Hamilton-Miller, 
2001). Some authors consider EGCG alone to be the active anticancer component, while 
others suggest that other tea constituents also have antiproliferative or anticarcinogenic 
properties (Jung & Ellis, 2001). Green tea extracts have been shown in vitro to stimulate 
apoptosis of various cancer cell lines, including prostate, lymphoma, colon, and lung (Yang 
et al., 2000; Mukhtar & Ahmad, 2000; Jung & Ellis, 2001; Gupta et al., 2003). Moreover, 
EGCG was reported to inhibit tumour invasion and angiogenesis, processes that are 
essential for tumour growth and metastasis (Jung & Ellis, 2001). Despite great efforts during 
the last two decades to understand the anticarcinogenic activity of tea, the exact 
mechanism(s) of action are not well defined. Therefore, deciphering the molecular 
mechanism by which green tea or its polyphenols impart their antiproliferative effects could 
be important and may result in improved opportunities for the treatment of cancer. 
Based on the observation that classical (MTX) and non-classical (TMP) antifolate compounds 
possess similar chemical structures to some tea polyphenols (Navarro-Perán et al., 2005a), 
we started to work on the hypothesis that tea catechins could inhibit DHFR activity. 
Suppression of DNA synthesis by tea catechins could explain many of the observed effects 
on cancer inhibition by these compounds. Recently, we have shown that ester bonded 
gallate catechins isolated from green tea, such as EGCG and ECG are potent inhibitors of 
DHFR activity in vitro at concentrations found in the serum and tissues of green tea drinkers 
(0.1–1.0 ǍM) (Navarro-Perán et al., 2005b). EGCG exhibited the kinetic characteristics of a 
slow-binding inhibitor of DHF reduction with bovine liver DHFR but of a classical, 
reversible, competitive inhibitor with chicken liver DHFR. Structural modelling showed that 
EGCG can bind to human DHFR in a similar orientation to that observed for a number of 
structurally characterized DHFR inhibitor complexes (Fig. 1) (Navarro-Perán et al., 2005a). 
These results suggested that EGCG could act as an antifolate compound in the same way as 
MTX and TMP. Since these first reports describing the inhibition of DHFR by tea 
polyphenols, several studies by us and other laboratories have reported that EGCG inhibits 
DHFR from a variety of biological sources (Navarro-Martínez et al., 2005; 2006; Navarro-
Perán et al., 2007; Hannewald et al., 2008; Kao et al., 2008; Spina et al., 2008; Sánchez-del-
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Campo et al., 2010a). Recently, a screening of DHFR-binding drugs by MALDI-TOFMS 
demonstrated that EGCG is an active inhibitor of DHFR and has a relative affinity between 
that of pyrimethamine and MTX (Hannewald et al., 2008). 
 
 
Fig. 1. View of EGCG modeled into the folate-binding site of human DHFR (Navarro-Perán 
et al., 2005a). Carbon atoms of the ECG ligand and surrounding protein are colored green 
and grey respectively. Residue Phe-31, located behind the EGCG, is unlabelled. Four 
different ligands from human and chicken DHFR crystal structures were used to define a 
binding envelope, shown in cyan; these were placed in a common orientation by 
superimposing backbone atoms from a common set of protein residues located around the 
ligands. Ligands from the following PDB structure files were used; 1DR1 (biopterin), 1S3V 
(TQD), 1S3W, and 1DLR. The figure was prepared using ViewerLite software.  
Other studies have been focused in understand weather the antifolate activity of tea catechins 
could explain their anti-inflammatory and antitumoral properties (Navarro-Perán et al., 2007; 
Navarro-Perán et al., 2008). The most common use of MTX is as an anticancer drug, although 
the drug is also considered to have anti-inflammatory and immuno-suppressive properties 
with accompanying activity against autoimmune disorders (Cutolo et al., 2001). Inflammation 
is central to our fight against pathogens, but if it is not ordered and timely the resulting chronic 
inflammation may contribute to diseases such as arthritis, heart attacks and Alzheimer’s 
disease. A functional link between chronic inflammation and cancer has long been suspected 
(Aggarwal, 2004; Balkwill & Coussens, 2004). This link is of great interest in the context of this 
chapter because green tea has shown remarkable anti-inflammatory activity (Sueoka et al., 
2001). Understanding the mechanisms by which EGCG imparts this effect could be of 
importance for explaining the epidemiological data on the prophylactic effects of diets high in 
gallate polyphenols for certain forms of cancer. Most solid tumors contain many non-
malignant cells, including immune cells and blood-vessel cells, which are important in 
inflammation, although the crucial molecular pathways that permit communication between 
abnormally growing cancer cells and these inflammatory cells remain unknown. A mouse 
model of inflammation-associated cancer now points to the involvement of the gene 
transcription factor NF-ǋB and the inflammatory mediator known as TNF-α in cancer 
progression (Pikarsky et al., 2004). Several of the anti-inflammatory effects of MTX and other 
antifolates can be explained by the suppression of NF-ǋB activation, a multisubunit factor 
known to play a role in inflammation, immune modulation and cell proliferation.  
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Although the mechanism by which antifolates modulate NF-B activation has remained 
unclear for some time, recent investigations have demonstrated that MTX could inhibit the 
TNF--induced NF-B activation though the release of adenosine (Cutolo et al., 2001; 
Majumdar & Aggarwal, 2001). By lowering THF cofactors, MTX inhibits two steps of the 
purine synthesis pathway: the conversion of GAR to FGAR and the conversion of AICAR to 
FAICAR. Excess AICAR inhibits the conversion of AMP to IMP by AMP deaminase, while 
AMP is rapidly converted to adenosine by surface expressed ecto-5’ nucleotidase. Adenosine 
is a potent endogenous regulator of a variety of physiological processes through specific 
receptors on the cell surface and binds to four different types of G protein-coupled cell surface 
molecules, termed the A1, A2A, A2B, and A3 adenosine receptors (Linden, 2001). After binding 
to the cell surface receptors, adenosine alters the immune cell production of soluble mediators 
such as cytokines, free radicals, and arachidonic acid metabolites (Majumdar & Aggarwal, 
2001). Although MTX is widely used for the treatment of inflammatory and autoimmune 
diseases, its use as a chemopreventive agent is precluded, even at low doses, due to its adverse 
side effects. However, there is no evidence for such side effects as a result of the regular 
consumption of tea. The finding that EGCG shares mechanisms of action with MTX could be 
of interest, and suggests that the regulation of chronic inflammation by EGCG could 
represents a strong possibility to explain the epidemiological data concerning the green tea’s 
prophylactic effects on certain forms of cancer (Yang et al., 2000). To check our hypothesis that 
the anti-inflammatory properties of EGCG could be related to its antifolate action and whether 
adenosine and its receptors are involved in EGCG action, we investigated the EGCG-induced 
suppression of NF-B in Caco-2 cell monolayer, which acted as a model of the human 
intestinal epithelium (Navarro-Perán et al., 2008). We observed that EGCG, by inhibiting 
DHFR, can disturb the metabolism of this vitamin in Caco-2 cells, producing the release of 
adenosine and the suppression of NF-B. The data suggest that by modulating NF-B 
activation, EGCG might not only combat inflammation, but also cancer. Since by reducing 
chronic inflammation there is a strong possibility of modulating tumorogenesis, these results 
could be of importance for explaining tea’s cancer preventive effects. 
4. Synthetic catechins as antifolate prodrugs against melanoma 
Despite the excellent properties of tea catechins, they have at least one limitation, their low 
bioavailability (Nakagawa & Miyazawa, 1997). Factors influencing this low bioavailability 
could be related to their low stability in neutral or slightly alkaline solutions and their inability 
to cross cellular membranes (Hong et al., 2002). In an attempt to solve such bioavailability 
problems, we first synthesized a 3,4,5-trimethoxybenzoyl analogue of ECG [3-O-(3,4,5-
trimethoxybenzoyl)-(-)-epicatechin, TMECG] (Sánchez-del-Campo et al., 2008). This 
compound was successfully synthesized following the five-step reaction sequence shown in 
Fig. 2, starting from the commercially available catechin. In comparing the antiproliferative 
activity of TMECG on several human and mouse cancer cell lines, we noticed that this 
compound was much more active on melanoma cells than on normal human melanocytes and 
other epithelial cancer cell lines from breast, lung and colon cancers (Sánchez-del-Campo et al., 
2008; Sánchez-del-Campo et al., 2009b). Next, we designed experiments to throw light on the 
elevated activity of TMECG on melanoma cell lines. As one of the most striking differences 
between melanoma and other epithelial cells is the presence of tyrosinase in melanoma, we 
wondered whether TMECG cytotoxicity against melanoma might be mediated by cellular 
tyrosinase activation. The results indicated that tyrosinase oxidized TMECG to its 
corresponding o-quinone, which quickly evolved through a series of chemical reactions to a 
quinone methide (QM), which showed high stability over a wide pH range (Fig. 3).  
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Fig. 2. Synthesis of TMECG (6) and TMCG (8). Reagents and conditions: (a) benzyl bromide, 
K2CO3, N,N-dimethylformamide, -10ºC to rt; (b) Dess-Martin periodinane, moist CH2Cl2, rt; 
(c) L-Selectride, n-Bu4NCl, THF, -78ºC; (d) 3,4,5-trimethoxybenzoyl chloride, 4, CH2Cl2, 
DMAP, rt; (e) H2, 20% Pd/C, THF/MeOH, rt. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3. Reaction sequences indicating the oxidation of TMECG and TMCG by tyrosinase and 
the formation of quinone methide (QM) species. 
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The TMECG-QM was found to be a potent irreversible inhibitor of human DHFR, and this 
highly stable product may be responsible for TMECG’s high activity against melanoma cells 
(Sánchez-del-Campo et al., 2009b). To explain the irreversibility on the binding of TMECG-
QM to human DHFR, we performed in silico molecular modelling experiments. TMECG 
bound to human DHFR in a similar way to that described for EGCG binding (Navarro-
Perán et al., 2005a), with specific hydrogen bonding interactions, most notably involving 
Glu-30 (Fig. 4). However, the open structure of QM increases its molecular flexibility, and it 
adopts a different conformation in the active site of human DHFR (Fig. 4). QM maintained 
the hydrogen bond with the Glu-30 side chain (O · · · ··O distance 1.99 Å), but three new 
interactions were detected. The other phenolic group of ring A forms a hydrogen bond with 
Ile-7, whereas the other two hydrogen bonds formed between two oxygens of the methoxy 
groups of ring D and Ser-59 and Ile-60. This strong interaction between QM and different 
residues of the protein could explain the irreversibility of the inhibitor-protein complex. 
Prodrugs are compounds that must be transformed before exhibiting their pharmacological 
action. They are often divided into two groups: those designed to increase bioavailability to 
improve the pharmacokinetics of antitumor agents, and those designed to deliver antitumor 
agents locally (Rooseboom et al., 2004). TMECG could, therefore, be considered an 
anticancer prodrug on melanoma since it showed both of these characteristics. Therapies 
with TMECG would increase bioavailability and would achieve high melanoma drug 
concentrations. The soft antifolate character (Graffner-Nordberg et al., 2004) of the prodrug 
(TMECG), its specific activation on melanoma cells and the fact that antifolates are more 
active on fast-dividing cancer cells make this compound ideal for the prevention and 
treatment of this skin pathology.  
However, the synthesis of TMECG is difficult and results in low yields. Therefore, we 
synthesized a related-epimer compound with catechin configuration [3-O-(3,4,5-
trimethoxybenzoyl)-(-)-catechin (TMCG)] (Fig. 2) (Sáez-Ayala et al., 2011). As observed in 
this figure TMECG and TMCG share the first synthesis step, but the yields of the other 
synthetic steps were significantly different. The overall yield of TMCG in the two steps of 
alkylation and deprotection was 88%; however, the overall yield of TMECG in the four steps 
of epimerisation of C-3 (oxidation and reduction), alkylation and deprotection was 16%. The 
difference between these yields was due to the limiting stereoselective reduction of 
compound 2 (Fig. 2), which gives moderate yield and purity and requires further 
purifications lowering the yield. Because of the absence of the limiting reduction step, the 
synthesis of TMCG was simpler (only three steps) and more economical (only common 
reagents). Since the active product of TMECG in melanoma is its QM derivative, we 
hypothesized that both TMECG and TMCG should have similar activity against these 
cancer cells (Sáez-Ayala et al., 2011). Oxidation of TMCG and TMECG by tyrosinase is 
predicted to generate the same final product because proton-catalysed hydrolysis of ring C 
would generate a freely rotating carbon (C-3), which should prevent epimeric differences in 
the QM product (Fig. 3). To confirm that TMECG and TMCG generate the same quinonic 
product after tyrosinase oxidation, both substrates were oxidised in vitro using mushroom 
tyrosinase as a catalyst. The final products of the corresponding oxidations were analysed 
and compared using several spectroscopic techniques. Tyrosinase oxidised TMECG and 
TMCG to stable final products, which varied in colour from yellow to orange depending on 
pH. The products had similar spectroscopic properties, with ǌmax at 275/412 nm at acidic 
pH and 275/470 nm at higher pH values (pKa = 6.9). Thus, the UV-Vis spectroscopy data 
indicated that, as represented in Fig. 3, both TMEGC and TMCG generated the same QM 
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product after tyrosinase oxidation. Mass spectroscopy confirmed these results, and the 
spectra of both final oxidation products exhibited the same molecular ion peak. High-
performance liquid chromatography-mass spectrometry (HPLC-MS) revealed that the 
molecular weights of the compounds were 498.7 (for TMECG) and 498.8 (for TMCG), which 
correspond to the calculated mass of the QM product depicted in Fig. 3. Both molecules 
were analysed by MS/MS and produced the same daughter ion peaks at m/z 363 and m/z 
287, corresponding to the loss of the dihydroxybenzoyl moiety and the trimethoxybenzoyl 
moiety, respectively.  
 
 
Fig. 4. Molecular modelling for the binding of TMECG and TMECG-QM to human DHFR. 
5. Antitumoral activity of TMECG in melanoma 
5.1 TMECG inhibits folate metabolism and transport in melanoma 
The folate cycle plays a central role in cell metabolism. Among its important functions are 
the delivery of one-carbon units to the methionine cycle for use in methylation reactions, 
and the synthesis of pyrimidines and purines. Several enzymes, including DHFR, TS and 
methyltetrahydrofolate reductase (MTHFR), participate in the activation and regeneration of 
folic acid coenzymes. Several studies have shown that the protein and mRNA levels of TS 
and DHFR are higher in tumor tissues and cancer cells than in their normal counterpart 
(Kufe et al., 1980; Rahman et al., 2004). Tumors with high levels of these enzymes are 
thought to undergo more active cellular proliferation, which, in turn, is associated with 
tumor invasiveness and metastasis. Having demonstrated the strong in vitro inhibition of 
human DHFR by QM, further experiments were designed to test its antifolate activity in 
culture systems. To investigate whether TMECG could interfere with folate metabolism in 
cancer cells, the levels of expression of these folate cycle genes were analyzed in melanoma 
SK-MEL-28 cells using real time PCR (Sánchez-del-Campo et al., 2008). As observed in other 
tumor tissues and cells, the genes involved in the metabolism of folic acid were highly 
overexpressed in melanoma cells compared with normal melanocytes. The levels of DHFR, 
TS and MTHFR mRNAs were calculated to be about 400-, 22- and 4-fold higher, 
respectively, in melanoma cells than in normal melanocytes. Treatment of SK-MEL-28 with 
TMECG produced a substantial and rapid downregulation of these genes, involving 
significant changes in the mRNA levels of the genes at 24 h of treatment. DHFR, TS and 
TMECG TMECG-QM 
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MTHFR mRNA levels were similar to that detected in normal melanocyte cells after 5 days 
of TMECG treatment. The data indicated that TMECG disturbs the folate metabolism in 
melanoma cells and suggest that this might be the mechanism by which TMECG induces 
cell growth inhibition and death. 
It is widely accepted that antifolates block the de novo biosynthesis of thymine, purines and 
pyrimidines by inhibiting the synthesis of THF, an essential cofactor in these biosynthetic 
pathways, and that the administration of exogenous reduced folates, such as leucovorin (5-
formyl-THF), or growing the cells in an HT-medium, effectively prevent antifolate 
cytotoxicity in mammalian cells. We observed that TMECG was more active on cells 
growing in a normal culture medium than in an HT medium (Sánchez-del-Campo et al., 
2009b); however, leucovorin did not “rescue” SK-MEL-28 cells from TMECG-induced death. 
Recently, it has been reported that natural tea catechins inhibit folate transport in Caco-2 
cells, which might be partly responsible for their antifolate activity (Alemdaroglu et al., 
2007). Therefore, to understand the different response of SK-MEL-28 to leucovorin- and HT-
treatments, and to prove or discard the in vivo antifolate activity of TMECG, the status of the 
RFC, the major protein involved in the transport of reduced folates, was analyzed in this cell 
line. RFC mRNA expression was significantly higher in SK-MEL-28 than in normal human 
melanocytes (8.9 times), but treating SK-MEL-28 with TMECG strongly downregulated RFC 
gene expression. The time-dependent effect of TMECG on SK-MEL-28 was studied using RT 
PCR, and the data indicated that cells responded quickly to TMECG treatment with a more 
than 80% reduction in RFC expression 24 h after treatment. Protein levels of this transporter 
correlated with gene expression (Sánchez-del-Campo et al., 2009b). This finding could 
explain why leucovorin did not affect TMECG treatments. As demonstrated, TMECG highly 
down-regulated the RFC and, therefore, SK-MEL-28 cells became practically impermeable to 
leucovorin during TMECG treatment and can not, therefore, restore the reduced folate 
levels in the cells. 
5.2 TMECG downregulates DHFR expression in melanoma 
As described for other cancer cell lines, DHFR is overexpressed in melanoma (Kufe et al., 
1980). The level of DHFR polyA+ mRNA in these melanoma cells was estimated to be 400 to 
500 times higher than in normal human melanocytes, resulting in increased DHFR protein 
content (Sánchez-del-Campo et al., 2009b). An increase in DHFR expression/activity after 
antifolate treatment has been recognized as a mechanism of resistance of cancer cells to 
antineoplastic drugs. As expected, treatment of SK-MEL-28 with MTX resulted in a 
significant increase of DHFR mRNA and protein. However, treatment of SK-MEL-28 with 
TMECG rapidly reduced DHFR mRNA and protein to normal levels. The efficient down-
regulation of DHFR by TMECG is evidence of its proposed antifolate activity. The lack of 
reduced folate coenzyme recycling by DHFR could be one of the reasons for its in vivo 
activity. 
The mechanism by which TMECG-QM downregulates DHFR expression in melanoma has 
been studied in more detail (Sánchez-del-Campo et al., 2010b). TMECG-QM has a dual 
action on these cells. First, it acts as a potent antifolate compound, disrupting folate 
metabolism and increasing intracellular oxidized folate coenzymes, such as DHF, which is a 
non-competitive inhibitor of dihydropterine reductase, an enzyme essential for 
tetrahydrobiopterin (H4B) recycling. Such inhibition results in H4B deficiency, endothelial 
nitric oxide synthase (eNOS) uncoupling and superoxide production. Second, TMECG-QM 
www.intechopen.com
 Novel Antifolates as Produgs for the Treatment of Melanoma 
 
111 
acts as an efficient superoxide scavenger and promotes intra-cellular H2O2 accumulation. 
We presented evidence that TMECG markedly reduces melanoma H4B and NO 
bioavailability and that TMECG action is abolished by the eNOS inhibitor N-nitro-L-
arginine methyl ester or the H2O2 scavenger catalase, which strongly suggested H2O2-
dependent DHFR downregulation (Sánchez-del-Campo et al., 2010b). It is this duality that 
may be of importance for TMECG action. Classical antifolate compounds are very effective 
in inhibiting DHFR but the lack of an antioxidant property may be the cause of the lack of 
DHFR downregulation. In cells treated with antifolates, the common effect is the 
overexpression of DHFR, which may be responsible for cell resistance to antifolates and is 
probably the reason that these compounds fail to treat melanoma (Zhao & Goldman, 2003). 
In addition, antioxidant therapies have little effect on melanoma. It is interesting to 
speculate that unsatisfactory outcomes of some of these antioxidant therapies are partially 
due to their ineffectiveness in uncoupling the eNOS reaction (Chalupsky & Cai, 2005). 
5.3 TMECG induces apoptosis in melanoma cells 
To investigate whether the metabolic changes induced by TMECG resulted in the apoptosis 
of melanoma cells, melanoma cell lines were treated for seven days with different 
concentrations of this compound and the degree of apoptosis induction was evaluated using 
a DNA fragmentation assay (Sánchez-del-Campo & Rodríguez-López, 2008). The results 
indicated that the reduced viability of melanoma cells in the presence of TMECG was 
indeed due to apoptosis induction. The data also indicated that normal melanocytes were 
highly resistant to TMECG-induced apoptosis, which is a highly desirable feature for 
potential antitumoral agents. TMECG-induced apoptosis was studied in greater detail using 
the SK-MEL-28 cell line. SK-MEL-28 cells exposed to 50 M TMECG for seven days showed 
evident signs of cellular damage. Morphological changes included cell shrinkage, loss of 
cell-cell contact and the fragmentation of plasmatic and nuclear membranes (Fig. 5). 
Another feature of apoptotic cell death, the activation of caspase-3, was evaluated by a 
colorimetric activity assay and Western blot analysis. The cells treated with TMECG showed 
significantly higher caspase-3 activity. Immunoblot analysis confirmed caspase-3 activation 
(Fig. 5). The Bcl-2 family proteins play a critical regulatory role through their interacting 
pro- and anti-apoptotic members, which integrate a wide array of upstream survival and 
distress signals to decide the fate of cells. Bax and Bcl-2 proteins are the key elements of this 
protein family. As reported for EGCG (Nihal et al., 2005), TMECG treatment resulted in a 
decrease in anti-apoptotic Bcl-2 and an increase in proapoptotic Bax at the levels of mRNA 
and protein, thereby resulting in a significant increase in the Bax/Bcl-2 ratio that favors 
apoptosis. Immunohistochemistry results also indicated that TMECG treatment caused 
mitochondrial translocation of Bax, which is a common response of cancer cells subject to 
certain apoptotic stimuli (Choi & Singh, 2005). 
In general, melanoma cells are quite resistant to apoptosis and it has recently been shown 
that these cells can avoid suicide by inactivating the apoptosis protease-activating factor-1 
(Apaf-1) gene, which is one step further on from p53 in the apoptosis pathway (Soengas et 
al., 2001). It was proposed that Apaf-1 inactivation involves the addition of methyl groups to 
cytosine nucleotides in DNA and the removal of acetyl groups from the hystone proteins 
that bundle DNA into the compressed form seen in the nucleus. In vivo, loss of expression of 
Apaf-1 has been associated with tumor progression, suggesting that Apaf-1 inactivation 
may provide a selective survival advantage to neoplastic cells (Soengas et al., 2001). To 
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Fig. 5. Apoptosis of SK-MEL-28 induced by TMECG visualized by the morphological aspect 
of untreated SK-MEL-28 cells compared with those subject to treatment with 50 M 
TMECG. The effect of TMECG on the protein content of caspase-3 in SK-MEL-28 was 
visualized by Western blot analysis in control cells (Sk28) and those treated with TMECG. 
Cells were treated for 7 days with 50 M TMECG 
evaluate the participation of Apaf-1 in SK-MEL-28 apoptosis during TMECG treatment, its 
mRNA and protein levels were determined by PCR and Western blot, respectively 
(Sánchez-del-Campo & Rodríguez-López, 2008). Apaf-1 mRNA and protein were detected 
in SK-MEL-28 and their levels were essentially the same than those detected in normal 
human melanocytes. This data indicated that, although methylation of Apaf-1 has been 
proposed as a mechanism for controlling its expression, TMECG, which decreased cellular 
methylation in SK-MEL-28 cells, was not able to produce Apaf-1 activation. These results are 
in accordance with others which found that drugs acting on different mechanisms did not 
induce or upregulate the expression of Apaf-1 at the levels of mRNA and protein (Zanon et 
al., 2004).  
5.4 TMEGC inhibits growth and metastasis of induced melanoma tumors in mice 
To check whether TMECG was pharmacologically active in in vivo situations and to study 
the possible inactivation of TMECG in the body, we performed experiments to test the 
effectiveness of this compound in induced melanoma tumors in mice. The group receiving 
TMECG therapy showed significantly longer survival times than the control group (Fig. 6).  
Moreover, we observed that tumor growth was significantly reduced by the treatment with 
TMECG but not with MTX (Fig. 6). The observation that TMECG-treated animals survived 
with larger tumors indicated that treatment could also reduce the metastasis of primary 
tumors. To confirm this, a third group was inoculated with B16 melanoma cells and treated 
with TMECG for 21 days (median survival time of the control group). After this time the 
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animals were sacrificed and a post-mortem examination of the lungs was performed to 
search for metastatic lesions. Secondary metastasis in the lungs was more frequent in control 
mice (Fig. 6), while treatment with TMECG drastically reduced lung metastasis. The lungs 
of the control animals showed prominent tumor nodules around the terminal bronchioles. 
These tumour nodules were composed of polygonal tumor cells with a prominent nucleolus. 
Intracellular melanin deposition and clear areas of necrosis were also detected. The lungs of 
the TMECG-treated tumor-bearing animals showed no significant tumor mass. The alveoli 
and pleura were tumor free, and the alveolar passage was lined with healthy ciliated 
columnar epithelial cells.  
 
 
Fig. 6. Inhibition of melanoma growth and metastasis by TMECG: (a) Median survival time 
following tumor implantation; (b) Mean tumor size in C57/B16 mice bearing B16 melanomas. 
(c) Rate of metastasis in postmortem and histological examination of lungs showing general 
aspect and histopathological analysis of lungs from C57/B16 mice bearing the B16 melanoma 
in control and TMECG-treated animals (Sánchez-del-Campo et al., 2009b). 
5.5 Proposed mechanism for the activation and antitumoral activity of TMEGC on 
melanoma 
Taken in consideration all these observations a mechanism for the activation, cellular 
distribution and action of TMECG and its products may now be proposed (Fig. 7). Although 
TMECG efficiently binds to DHFR, we hypothesized that this hydrophobic compound 
would cross the cell membrane without needing to bind to folate transporters. Therefore, the 
most plausible transport mechanism for this lipophilic drug is passive diffusion across the 
plasma membrane in a manner driven solely by the concentration gradient (Fig. 7a). Its 
independence from folate transporters means that TMECG may avoid transport-mediated 
resistance mechanisms (Ma et al., 2000). In fact, TMECG downregulated RFC but, far from 
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Fig. 7. Schematic mechanism underlying activation, cellular distribution and action of 
TMECG in melanoma cells (Sánchez-del-Campo et al., 2010b). 
being a disadvantage, this could represent an important advantage for its antiproliferative 
action. Downregulation of RFC would reduce intracellular folate pools, reducing competition 
reactions with the active form of TMECG and the molecular target, DHFR. Subsequent 
transport to the melanosome by a concentration gradient would facilitate its tyrosinase-
catalyzed oxidation and transformation to the corresponding QM (Fig. 7b). Observations from 
our laboratory indicated that TMECG or TMECG-QM did not interact with DOPA-melanins, 
which may avoid melanosomal trapping. Because of the low pH of this organelle, the 
predominant form is QMH, which, due to its high stability and the absence of formal charge, 
would exit the melanosome and enter the cytosol (Fig. 7c). Under the slightly basic pH of the 
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cytosol, the anionic form of QM would be the predominant form, and it would be trapped in 
this compartment due to its formal negative charge. This retention mechanism would 
represent another advantage with respect to antifolates that require polyglutamylation for 
cellular retention. This would be even more essential in cancer cell environments, in which 
folate requirements lead to an increase in the cellular THF-cofactor pools. As the THF-cofactor 
pool is increased, there is a feedback inhibition of folate polyglutamylation, which results in 
the accumulation of easily exported compounds (Tse & Moran, 1998). Once in the cytosol, 
TMECG-QM may inhibit DHFR activity and, in addition, lead to the downregulation of DHFR 
(Fig. 7d-h). The finding that tyrosinase is highly overexpressed in melanoma cells with respect 
to normal melanocytes might also influence the degree, the specificity and the duration of the 
antifolate inhibitory effect of TMECG-QM. Finally, the data on the effectiveness of TMECG in 
mouse melanoma models indicates that TMECG is bioavailable for cancer cells and avoids not 
only cellular mechanisms of resistance to antifolates but also mechanisms related with body 
drug inactivation. 
6. Combined therapies to improve the activity of synthetic catechins in 
melanoma 
The combination of several drugs to improve the clinical efficiency of the treatments is a 
common strategy for the fighting of pathological bacteria. For instance, TMP is used in 
combination with sulphonamides as a therapy against multiple bacterial infections. These 
are treatment based in the metabolic attack of the bacteria, where TMP inhibits the recycling 
of folic acid coenzymes and the sulphonamide inhibits the synthesis of folic acid. 
Conventional chemotherapy treatments against cancer have shown important clinical 
limitations and, therefore, it would be of interest to develop new and more efficient 
strategies for the treatment of this fatal pathology. The metabolic attack of cancer cells could 
be an interesting perspective. The identification of metabolic and signalling pathways 
essential for tumour growth and dissemination, but less important for healthy cells, could 
guide the development of new cancer therapies. The combination of several drugs to target 
several metabolic and/or signalling pathways could increase the efficiency of the 
treatments. Recently, it has been observed that the major catechin presented in green tea, 
EGCG, showed synergic activity with other drugs commonly used for the treatment of 
several cancers and in some cases EGCG sensitizes cancer cells to other treatments (Liu et 
al., 2001; Farabegoli et al., 2007). The identification of synthetic catechins as antifolate 
compounds can help the design of more directed combined therapies against melanoma 
since the folic acid has multiple connections with metabolic and signalling pathways. Thus, 
we started this application targeting the methionine cycle in melanoma using TMECG in 
combination with other drugs (Fig. 8). 
Malignant tumors are characterized by a high rate of growth. Tumor cells drain the energy 
of the host, particularly glucose but also amino acids. Methionine is an essential amino acid 
with at least four major functions (Fig. 8) (Cellarier et al., 2003). First, methionine 
participates in protein synthesis. Second, methionine is a precursor of glutathione, a 
tripeptide that reduces reactive oxygen species, thereby protecting cells from oxidative 
stress (Anderson, 1998). Third, it is required for the formation of polyamines, which have 
far-ranging effects on nuclear and cell division (Thomas & Thomas, 2001). Fourth, 
methionine is the major source of the methyl groups necessary for the methylation of DNA 
and other molecules (Cellarier et al., 2003). It is important to bear in mind the well-
established connection of the methionine cycle with two crucial cell metabolites, folic acid 
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and adenosine (Fig. 8). Folic acid acts as the fuel for the methionine cycle, which, after 
transformation by folate cycle enzymes such as DHFR, TS and MTHFR, forms 5-methyl-
THF, the cofactor of methionine synthase (MS), the enzyme responsible for methionine 
synthesis (Fig. 8). Adenosine, in contrast, is a product of the methionine cycle, and is 
produced at high concentrations in tumor cells. The efficient intracellular elimination of this 
product by adenosine-transforming enzymes, such as adenosine deaminase (ADA), or its 
transport out of the cells by specific adenosine transporters, including the equilibrate 
nucleoside transporters (ENTs), is of vital importance for cancer cell survival.  
The efficacy of antifolates in treating cancer is widely attributed to the subsequent decrease 
in nucleotide production, but in addition to these effects, antifolate treatment has also been 
linked to a decrease in cellular methylation. We observed that TMECG modulated the 
expression of genes involved in methionine metabolism, cellular methylation and 
glutathione synthesis in melanoma cells (Sánchez-del-Campo & Rodríguez-López, 2008). 
Having elucidated the effects of TMECG on the melanoma folate and methionine cycles, we 
designed therapeutical strategies to increase its effectiveness. Combinations of TMECG with 
S-adenosylmethionine (SAM) or compounds that modulate the intracellular concentration of 
adenosine strongly increase the antiproliferative effects of TMECG. The ability of TMECG to 
target multiple aspects related with melanoma survival, with a high degree of potency, 
points to its clinical value in melanoma therapy. 
 
 
Fig. 8. The methionine cycle and its connections with several metabolic and survival cell 
pathways. Abbreviations: ADA, adenosine deaminase; AHYC, S-adenosylhomocysteine 
hydrolase; COMT, catechol-O-methyltransferase; DHF, dihydrofolate; DHFR, dihydrofolate 
reductase; DNMT, DNA methyltransferase; ENT, equilibrative nucleoside transporter; GCS, -
glutamylcysteine synthetase; MAT, methionine adenosyltransferase; MS, methionine synthase; 
MTHFR, 5,10-methylenetetrahydrofolate reductase; SAH, S-adenosylhomocysteine; SAM, S-
adenosylmethionine; THF, tetrahydrofolate; TS, thymine synthase. 
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6.1 SAM enhances the antiproliferative effects of TMECG 
Having analyzed the ability of TMECG to disrupt the methionine cycle, we designed several 
strategies to completely block this pathway. The first strategy was to inhibit methionine 
adenosyltransferase-2A (MAT2A) enzyme (Fig. 8). MAT2A shows a very low Km for 
methionine (4-10 M) and, in tissues that predominantly express MAT2A, the rate of SAM 
synthesis is near maximal and relatively unaffected by fluctuations in methionine 
concentration and, thus, MAT2A can work even a very low concentration of methionine. 
Another kinetic characteristic of MAT2A is that this enzyme is strongly inhibited by SAM, 
its reaction product (IC50 = 60 M) (Sullivan & Hoffman, 1983). We hypothesized that, by 
increasing intracellular SAM concentration in the presence of TMECG, two consecutive 
steps in the methionine cycle, the synthesis of methionine and the synthesis of SAM, could 
be blocked (Fig. 8). Only high concentrations of SAM (up to 100 M) affected SK-MEL-28 
growth in accordance with its calculated IC50 towards MAT2A. However, in the presence of 
TMECG, lower concentrations of SAM showed a synergistic behavior with this antifolate 
compound. Thus, the combination 20 M SAM with 50 M TMECG efficiently inhibited the 
growth of SK-MEL-28. The results indicated that when MAT2A is working at limiting 
concentrations of methionine in the presence of TMECG, it is highly susceptible to inhibition 
by low SAM concentrations. 
6.2 Strategies to increase the intracellular concentration of adenosine in the  
presence of TMECG 
As observed in Fig. 8, adenosine is a direct product of the methionine cycle, and is produced 
in high concentration when the cycle is highly active. Any resulting excess of adenosine may 
not be a problem for cancer cells. Adenosine is efficiently metabolized by specific enzymes 
such as ADA and adenosine kinase (ADK) before being used for purine nucleotide 
synthesis, which is even more necessary for DNA synthesis in these highly proliferating 
cells. Finally, excess adenosine can be transported out of the cells by ENTs, bidirectional 
transporters that allow adenosine release and uptake by facilitating diffusion along its 
concentration gradient. However, in the presence of an antifolate compound, adenosine 
accumulation might represent a severe problem for the cell. Depletion of 5-methyl-THF 
would result in the production of high concentrations of S-adenosylhomocysteine (SAH), 
which strongly inhibits cellular methyltransferases. This inhibition would produce an 
accumulation of SAM, which would inhibit the MAT2A reaction. We hypothesized that 
accumulation of adenosine in the presence of TMECG may block the methionine cycle at 
three levels: the synthesis of methionine, the methylase reaction and the synthesis of SAM 
(Fig. 8). Adenosine flux across the cellular membrane depends on the concentration 
gradients between extra- and intracellular nucleoside levels (Tabrizchi & Bedi, 2001). 
Therefore, we first tried to increase the extracellular concentration of adenosine. Adenosine 
alone had no detectable effect on SK-MEL-28 growth at the studied concentrations (up to 
500 M) but, in the presence of TMECG, adenosine had a significant synergistic effect, 
enhancing the antiproliferative action of this antifolate compound. A combination of 50 M 
adenosine with 50 M TMECG was seen to completely inhibit the growth of SK-MEL-28.  
Although adenosine is currently used for the treatment of several cardiovascular diseases, 
its use as a therapeutic agent is restricted, since it is rapidly metabolized to inosine and 
AMP, which limits its ability to exert a systemic effect. Therefore, we planned other strategy 
to accumulate adenosine in melanoma cells using dipyridamole. This drug suppresses 
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adenosine transport by inhibiting ENTs. Moreover, it also inhibits the enzyme ADA, which 
normally breaks down adenosine into inosine. We hypothesized that inhibition of ENTs and 
ADA in melanoma cells would result in an intracellular accumulation of adenosine, which, 
in the presence of TMECG-accumulated homocysteine, would produce an effective blockage 
of the methionine cycle. Dipyridamole alone inhibited SK-MEL-28 growth with a calculated 
IC50 (at 5 days) of 20 M. However, in the presence of 50 M TMECG, the IC50-value fell to 
less than 1 M. A combination of 5 M dipyridamole with 50 M TMECG had a deadly 
effect on melanoma cells. The results pointed to the possibility of using this combination 
treatment against malignant melanoma. 
6.3 Methionine depletion for melanoma treatment: Conclusions 
Conventional chemotherapy treatments have shown their limits, especially for patients with 
advancer cancer. New therapeutic strategies must be identified, and the metabolic 
abnormalities of cancer cell open up such opportunities (Cellarier et al., 2003). Many human 
cancer cells lines and primary tumors have an absolute need for methionine, an essential 
amino acid. In contrast, normal cells are relatively resistant to exogenous methionine 
restriction. We show that melanoma cells are highly dependent on methionine. The 
resistance of melanomas to general chemotherapies and their avoidance of cellular suicide 
or resistance to apoptosis is primarily related with the high activity of the methionine cycle 
in these cells, which permits the methylation of specific genes and activation of different 
survival pathways. Blockage of the methionine cycle by the new antifolate, TMECG, is an 
effective therapy for melanoma. The specific activity of TMECG on melanoma methionine 
cycle was confirmed by the high synergy found with compounds that uncoupled adenosine 
metabolism in these cells. In conclusion, our results show that TMECG is a potent antitumor 
agent that modulates multiple aspects of melanoma metabolism and survival, including the 
folic acid and the methionine cycles and the methylation status of the cells. This broad 
spectrum of antitumor activities in conjunction with low toxicity underlies the translational 
potential of TMECG and suggests it may be used as part of a therapeutic strategy against 
melanoma. A combination with other compounds that modulate melanoma methionine 
cycle, such as SAM, adenosine or dipyridamole, represents another promising strategy to 
combat this malignant skin pathology.  
7. Conclusions 
Several investigations indicate that natural and synthetic polyphenols may well be 
beneficial, not only in the prevention but also in the treatment of cancer. Antifolates are 
usually used as chemotherapeutic agents for certain types of cancer. Although antifolates 
such as MTX attack proliferating tissues selectively, they are also toxic to normal cells. 
Deleterious side effects are seen against tissues that proliferate as part of their normal 
function; such tissues include intestinal mucosa, hair cells, and components of the immune 
system. The “soft” character of polyphenols could be developed for use in the treatment of 
cancer with significantly reduced side effects compared to those of the DHFR inhibitors 
currently in use in chemotherapy such as MTX. Moreover, we have demonstrated that 
synthetic derivatives of ECG, TMECG and TMCG, might be considered a treatment for 
melanoma. Disruption of the cell folate cycle by these compounds and their active products 
may explain many of the molecular and cellular effects described for these synthetic 
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polyphenols on melanoma cells because antifolates exert their action by disturbing the 
nucleic acid metabolism of cancer cells, including its synthesis, methylation and stability 
(Navarro-Perán et al., 2007; Sánchez-del-Campo & Rodríguez-López, 2008). We define them 
as new generation antifolates because they maintain the ability to inhibit DHFR and disrupt 
folate metabolism but show significant and important differences from other classical and 
non-classical antifolates. TMECG was seen to be active not only in melanoma cells in culture 
but was also effective in an animal model, where it inhibited growth and metastasis of 
preformed tumors. An additional advantage of these compounds is their prodrug character, 
which would favour its specific activity against melanoma cells and prevent unspecific side 
effects in rapidly dividing healthy cells. In addition, the multiple connections of the folic 
acid cycle with many metabolic and signalling pathways in melanoma cells could open the 
way for the development of new combined and directed therapies against this elusive skin 
pathology. 
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